218 related articles for article (PubMed ID: 21361909)
1. Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes.
Tohn R; Blumenfeld H; Haeryfar SM; Veerapen N; Besra GS; Porcelli SA; Delovitch TL
Clin Exp Immunol; 2011 Apr; 164(1):26-41. PubMed ID: 21361909
[TBL] [Abstract][Full Text] [Related]
2. Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice.
Blumenfeld HJ; Tohn R; Haeryfar SM; Liu Y; Savage PB; Delovitch TL
Clin Exp Immunol; 2011 Oct; 166(1):121-33. PubMed ID: 21910729
[TBL] [Abstract][Full Text] [Related]
3. An alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes.
Ly D; Tohn R; Rubin B; Blumenfeld H; Besra GS; Veerapen N; Porcelli SA; Delovitch TL
Clin Exp Immunol; 2010 May; 160(2):185-98. PubMed ID: 20015094
[TBL] [Abstract][Full Text] [Related]
4. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
5. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
[TBL] [Abstract][Full Text] [Related]
6. β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy.
O'Konek JJ; Kato S; Takao S; Izhak L; Xia Z; Illarionov P; Besra GS; Terabe M; Berzofsky JA
Clin Cancer Res; 2013 Aug; 19(16):4404-11. PubMed ID: 23804426
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.
Akbari O; Stock P; Singh AK; Lombardi V; Lee WL; Freeman GJ; Sharpe AH; Umetsu DT; Dekruyff RH
Mucosal Immunol; 2010 Jan; 3(1):81-91. PubMed ID: 19741598
[TBL] [Abstract][Full Text] [Related]
8. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
Durgan K; Ali M; Warner P; Latchman YE
Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487
[TBL] [Abstract][Full Text] [Related]
9. α-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3.
Huang JR; Tsai YC; Chang YJ; Wu JC; Hung JT; Lin KH; Wong CH; Yu AL
J Immunol; 2014 Feb; 192(4):1972-81. PubMed ID: 24465013
[TBL] [Abstract][Full Text] [Related]
10. A Novel Liposome Formulation Carrying Both an Insulin Peptide and a Ligand for Invariant Natural Killer T Cells Induces Accumulation of Regulatory T Cells to Islets in Nonobese Diabetic Mice.
Akimoto H; Fukuda-Kawaguchi E; Duramad O; Ishii Y; Tanabe K
J Diabetes Res; 2019; 2019():9430473. PubMed ID: 31781669
[TBL] [Abstract][Full Text] [Related]
11. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.
Hong S; Wilson MT; Serizawa I; Wu L; Singh N; Naidenko OV; Miura T; Haba T; Scherer DC; Wei J; Kronenberg M; Koezuka Y; Van Kaer L
Nat Med; 2001 Sep; 7(9):1052-6. PubMed ID: 11533710
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells.
Parekh VV; Lalani S; Kim S; Halder R; Azuma M; Yagita H; Kumar V; Wu L; Kaer LV
J Immunol; 2009 Mar; 182(5):2816-26. PubMed ID: 19234176
[TBL] [Abstract][Full Text] [Related]
13. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
Rosalia RA; Štěpánek I; Polláková V; Šímová J; Bieblová J; Indrová M; Moravcová S; Přibylová H; Bontkes HJ; Bubeník J; Sparwasser T; Reiniš M
Immunobiology; 2013 Jun; 218(6):851-9. PubMed ID: 23182710
[TBL] [Abstract][Full Text] [Related]
14. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes.
Chen YG; Choisy-Rossi CM; Holl TM; Chapman HD; Besra GS; Porcelli SA; Shaffer DJ; Roopenian D; Wilson SB; Serreze DV
J Immunol; 2005 Feb; 174(3):1196-204. PubMed ID: 15661873
[TBL] [Abstract][Full Text] [Related]
15. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.
Kharkwal SS; Johndrow CT; Veerapen N; Kharkwal H; Saavedra-Avila NA; Carreño LJ; Rothberg S; Zhang J; Garforth SJ; Jervis PJ; Zhang L; Donda A; Besra AK; Cox LR; Almo SC; Howell A; Evans EE; Zauderer M; Besra GS; Porcelli SA
Cancer Res; 2021 Apr; 81(7):1788-1801. PubMed ID: 33483371
[TBL] [Abstract][Full Text] [Related]
16. Activation of natural killer T cells by α-carba-GalCer (RCAI-56), a novel synthetic glycolipid ligand, suppresses murine collagen-induced arthritis.
Yoshiga Y; Goto D; Segawa S; Horikoshi M; Hayashi T; Matsumoto I; Ito S; Taniguchi M; Sumida T
Clin Exp Immunol; 2011 May; 164(2):236-47. PubMed ID: 21391989
[TBL] [Abstract][Full Text] [Related]
17. Invariant natural killer T-cell control of type 1 diabetes: a dendritic cell genetic decision of a silver bullet or Russian roulette.
Driver JP; Scheuplein F; Chen YG; Grier AE; Wilson SB; Serreze DV
Diabetes; 2010 Feb; 59(2):423-32. PubMed ID: 19903740
[TBL] [Abstract][Full Text] [Related]
18. Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation.
Iyoda T; Ushida M; Kimura Y; Minamino K; Hayuka A; Yokohata S; Ehara H; Inaba K
Int Immunol; 2010 Nov; 22(11):905-13. PubMed ID: 21118907
[TBL] [Abstract][Full Text] [Related]
19. Modulation of NKT cells and Th1/Th2 imbalance after alpha-GalCer treatment in progressive load-trained rats.
Ru W; Peijie C
Int J Biol Sci; 2009 May; 5(4):338-43. PubMed ID: 19461936
[TBL] [Abstract][Full Text] [Related]
20. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells.
Ly D; Mi QS; Hussain S; Delovitch TL
J Immunol; 2006 Sep; 177(6):3695-704. PubMed ID: 16951329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
